



ASX Release

Kansas University Joins PTX's Acute Myeloid Leukemia Phase 1b/2 Trial

Melbourne, Australia (8 May 2017): Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is pleased to announce that the University of Kansas Medical Center (KUMC) in Kansas City, Kansas, will join PTX's Phase 1b/2 clinical trial in acute myeloid leukemia (AML).

The study is currently dosing its second cohort of patients at the H. Lee Moffitt Cancer Center (Moffitt) in Florida and is also expected to recruit its first patients at the Yale Cancer Center (Yale) shortly.

The trial will be undertaken with PTX's novel Akt inhibitor PTX-200 plus cytarabine in refractory or relapsed acute leukemias, treating 15-18 patients in escalating doses.

Recruitment at Kansas will be led by Associate Professor Tara Lin, Director, Acute Leukemia Program in the Division of Hematologic Malignancies at the University of Kansas Cancer Center.

Dr. Lin said "There is an urgent need for new treatments for AML, particularly in the relapsed and refractory settings. Previous studies with PTX-200 at MD Anderson and Moffitt Cancer Centre demonstrated activity in hematological cancers. This is an important, well-designed study, and I am pleased to offer this regimen to our patients."

KUMC's cancer center is one of only 68 National Cancer Institute-designated cancer centers in the US and is one of 62 institutions in the national Clinical and Translational Science Award consortium.

PTX CEO, Steven Yatomi-Clarke said "Associate Professor Lin has an outstanding reputation in acute leukemias and we are honored to have her and KUMC involved in our AML study.

KUMC is a prestigious medical institution with an excellent track record in cancer research and patient care. Its location in the Midwest of the US also provides geographical diversification for our recruitment. Coupled with Moffitt and Yale, the study is well positioned to meet its patient recruitment target of enrollment completion this calendar year."

ENDS

About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors



that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt); Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440